메뉴 건너뛰기
Lancet
Volumn 361, Issue 9375, 2003, Pages 2094-2095
Chemotherapy for recurrent ovarian cancer
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM;
EID: 0037863002     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13726-9     Document Type: Note
Times cited : (11)
References (7)
  • 1
    • 0037125582 scopus 로고    scopus 로고
    • Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: The ICON 3 randomised trial
    • Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet. 360:2002;505-515.
    • (2002) Lancet , vol.360 , pp. 505-515
  • 2
    • 0025103224 scopus 로고
    • Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
    • Gore M.E., Fryatt I., Wiltshaw E., et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
    • (1990) Gynecol Oncol , vol.36 , pp. 207-211
    • Gore, M.E.1    Fryatt, I.2    Wiltshaw, E.3
  • 3
    • 0037033738 scopus 로고    scopus 로고
    • Weekly cisplatin and daily oral etoposide is highly effective in platinum pre-treated ovarian cancer
    • Van der Burg M.E., de Wit R., Van Putton W.L., et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pre-treated ovarian cancer. B J Cancer. 7:2002;19-25.
    • (2002) B J Cancer , vol.7 , pp. 19-25
    • Van Der Burg, M.E.1    De Wit, R.2    Van Putton, W.L.3
  • 4
    • 0037686685 scopus 로고    scopus 로고
    • Randomised phase II study of carboplatin versus paclitaxel-carboplatin in platinum-sensitive recurrent advanced ovarian cancer: A GEICO study
    • abstr
    • Gonzalez-Martin A., Calvo E., Bover I., et al. Randomised phase II study of carboplatin versus paclitaxel-carboplatin in platinum-sensitive recurrent advanced ovarian cancer: a GEICO study. Proc ASCO. 22:2003;451. abstr.
    • (2003) Proc ASCO , vol.22 , pp. 451
    • Gonzalez-Martin, A.1    Calvo, E.2    Bover, I.3
  • 5
    • 0037037385 scopus 로고    scopus 로고
    • First-line treatment for advanced ovarian cancer; Paclitaxel, platinum and the evidence
    • Sandercock J., Parmar M.K., Torri V., Quain W. First-line treatment for advanced ovarian cancer; paclitaxel, platinum and the evidence. B J Cancer. 87:2002;815-824.
    • (2002) B J Cancer , vol.87 , pp. 815-824
    • Sandercock, J.1    Parmar, M.K.2    Torri, V.3    Quain, W.4
  • 6
    • 0037037326 scopus 로고    scopus 로고
    • First line chemotherapy for ovarian cancer - The controversy continues
    • Kaye S.B. First line chemotherapy for ovarian cancer - the controversy continues. B J Cancer. 87:2002;813-814.
    • (2002) B J Cancer , vol.87 , pp. 813-814
    • Kaye, S.B.1
  • 7
    • 0030026934 scopus 로고    scopus 로고
    • Loss of normal p53 function confers sensitisation to Taxol by increasing G2/M arrest and apoptosis
    • Wahl A.F. Loss of normal p53 function confers sensitisation to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 2:1996;72-79.
    • (1996) Nat Med , vol.2 , pp. 72-79
    • Wahl, A.F.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.